Read More Pharma Industry News Valneva slashes 2025 outlook after FDA suspends Ixchiq license, shaking investor confidence Valneva slashes 2025 outlook after FDA suspends Ixchiq license—discover how the biotech aims to rebuild confidence and cash flow stability. byVenkateshOctober 6, 2025